Important Keyword: Notification No. 05/2024 Central Tax Rate, GST Rate Notification 2024, Trastuzumab GST, GST on snacks, Osimertinib GST rate, GST on vehicle seats, CBIC updates October 2024,
Words: 1327; Read time: 7 minutes
Table of Contents
[F. No. CBIC-190354/149/2024-TO(TRU-II)]
GOVERNMENT OF INDIA
MINISTRY OF FINANCE
(Department of Revenue)
New Delhi, the 8th October, 2024
Notification No. 05/2024 - Central Tax (Rate): Seeks to amend Notification No. 1/2017- Central Tax (Rate) dated 28.06.2017.
GST [TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY, PART II, SECTION 3, SUB- SECTION (i)]
G.S.R (E).- In exercise of the powers conferred by sub-section (1) of section 9 and sub-section (5) of section 15 of the Central Goods and Services Tax Act, 2017 (12 of 2017), the Central Government, on the recommendations of the Council, hereby makes the following further amendments in the notification of the Government of India, Ministry of Finance (Department of Revenue), No. 1/2017-Central Tax (Rate), published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 673(E), dated the 28th June, 2017, namely:-
In the said notification, -
- after Schedule I – 2.5% , in List 1, after item number 232 and the entries relating thereto, the following item numbers and entries shall be inserted, namely: -
“(233) Trastuzumab Deruxtecan
- Osimertinib
- Durvalumab”;
- in Schedule II – 6%, after S. No. 32B and the entries relating thereto, the following S. No. and entries shall be inserted, namely: -
| “32C | 1905 90 30 | Extruded or expanded products, savoury or salted (other than un-fried or un- cooked snack pellets, by whatever name called, manufactured through process of extrusion)”; |
- in Schedule III – 9%, -
- against S. No. 16, in column (3), for the words “un-fried or un-cooked snack pellets, by whatever name called, manufactured through process of extrusion”, the words “un-fried or un-cooked snack pellets, by whatever name called, manufactured through process of extrusion, extruded or expanded products, savoury or salted” shall be substituted;
- for S. No. 435A and the entries relating thereto, the following S. No. and entries shall be substituted, namely: -
| “435A | 9401 [other than 9401 10 00 or 9401 20 00] | Seats (other than those of heading 9402), whether or not convertible into beds and parts thereof other than seats of a kind used in aircraft or seats of a kind used for motor vehicles”; |
- in Schedule IV – 14%, after S. No. 210 and the entries relating thereto, the following S. No. and entries shall be inserted, namely: -
| “210A | 9401 20 00 | Seats of a kind used for motor vehicles”. |
2. This notification shall come into force on the 10th day of October, 2024.
(Amreeta Titus)
Deputy Secretary
Note: - The principal notification No. 1/2017-Central Tax (Rate), dated the 28th June, 2017, was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 673(E), dated the 28th June, 2017, and was last amended vide notification No. 2/2024 – Central Tax (Rate), dated the 12th July, 2024, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R. 396(E), dated the 12th July, 2024.
📚 Frequently Asked Questions (FAQs): Notification No. 06/2024 - Central Tax (Rate)
Q1: 🧾 What is Notification No. 05/2024 - Central Tax (Rate)?
Answer:
Notification No. 05/2024-Central Tax (Rate), issued on 8th October 2024, introduces amendments to the GST rate structure outlined in Notification No. 1/2017-Central Tax (Rate). It modifies product listings across Schedules I to IV and updates applicable GST rates for specific goods, including life-saving drugs, snack products, and automotive seating. This notification becomes effective from 10th October 2024.
Q2: 💉 Which new pharmaceutical items were added under Schedule I at 2.5% GST?
Answer:
As per the notification, the following anti-cancer and immunotherapy drugs are now taxed at 2.5% under Schedule I:
✅ Trastuzumab Deruxtecan
✅ Osimertinib
✅ Durvalumab
These life-saving drugs are essential treatments for patients and their GST rates have been reduced to improve affordability. For personalized GST compliance support, consult a GST Expert at www.Finodha.in.
Q3: 🍟 What changes were made to Schedule II – 6% GST slab?
Answer:
A new item, classified under HS Code 1905 90 30, has been introduced:
✅ “Extruded or expanded products, savoury or salted (excluding un-fried/un-cooked snack pellets)”
This change distinguishes processed snack items from their raw counterparts. For help determining your product classification, visit our GST Registration portal: https://finodha.in/online-gst-registration/
Q4: 🍘 How does this impact Schedule III – 9% tax slab?
Answer:
Schedule III now clarifies that it includes:
🟢 “Un-fried or un-cooked snack pellets… AND extruded or expanded savoury/salted products.”
Also, the scope of S. No. 435A is revised to include:
✅ All seats (except aircraft/motor vehicles & medical use), convertible or not.
This adjustment ensures accurate classification across seating product ranges. Need guidance? Speak to GST professionals at https://finodha.in/gst-compliance/
Q5: 🚗 What is the new addition under Schedule IV (14% GST)?
Answer:
A new S. No. 210A has been inserted under Schedule IV:
✔️ 9401 20 00 – “Seats of a kind used for motor vehicles”
This move creates a clear rate distinction between general seating and those designed specifically for automobiles. Learn how to optimize GST filings by visiting: https://finodha.in/gst-return-filing/
Q6: 📆 From when is Notification No. 05/2024 effective?
Answer:
The changes introduced through Notification No. 05/2024-Central Tax (Rate) come into force on 10th October 2024. Businesses dealing with pharmaceuticals, snacks, or vehicle parts must ensure timely updates to their billing systems. For a smooth GST transition, visit: https://finodha.in/gst-compliance/
Q7: 📚 Which earlier notifications does it amend?
Answer:
This notification amends:
👉 Notification No. 1/2017 - Central Tax (Rate), dated 28 June 2017
👉 The latest amendment before this was Notification No. 2/2024, dated 12 July 2024
For a detailed understanding of historic GST updates, access our expert GST library at: https://finodha.in/
Q8: 🛍️ How does this affect traders and manufacturers?
Answer:
Manufacturers and suppliers of medical drugs, extruded food products, and seating goods must re-evaluate their invoicing systems and HSN code mappings. Incorrect classifications can lead to penalties or ITC mismatches. Leverage Finodha’s ITR and compliance tools for peace of mind: https://finodha.in/income-tax-return-filing-online/
Q9: 🧾 Where can I get GST registration or compliance help for affected items?
Answer:
Finodha offers dedicated GST support for new businesses, manufacturers, exporters, and wholesalers. Services include:
🔸 Online GST Registration: https://finodha.in/online-gst-registration/
🔸 GST Return Filing: https://finodha.in/gst-return-filing/
🔸 Setup Business Support: https://finodha.in/setup-business/
Q10: 🧠 Is expert GST consultation available for businesses unsure about classification?
Answer:
Absolutely. Misclassification can lead to ITC loss or penalty. Our GST Experts at www.Finodha.in can help assess your product, apply the right schedule slab, and keep your tax filings compliant with the latest CBIC guidelines.
📌 Summary:
Notification No. 05/2024-Central Tax (Rate) introduces important updates affecting pharmaceuticals, food products, and vehicle seating. Understanding these updates ensures that your business remains compliant and optimized under the latest GST framework. Access professional guidance and automation tools through Finodha.in to stay ahead in compliance and filings.
📣 Pro Tip:
Bookmark Finodha's GST compliance page to never miss an update: https://finodha.in/gst-compliance/
Download PDF: Notification No. 05/2024 - Central Tax (Rate)
More Information: https://taxinformation.cbic.gov.in/
Read more interesting articles:



